Resources for You
Desferal (deferoxamine mesylate) for injection
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2011
- Monitor patients for changes in renal function.
- No studies have been performed in patients with hepatic impairment.
- Acute respiratory distress syndrome has been reported following treatment with excessively high intravenous doses of Desferal in patients with acute iron intoxication and in patients with thalassemia.